Clarissa A. Pisano

Ferrara, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Identification of DARPP-32 as a novel sleep regulator in physiological conditions and experimental Parkinsonism.

Identification of DARPP-32 as a novel sleep regulator in physiological conditions and experimental Parkinsonism.

Journal: iScience

Published: September 10, 2025

A mouse model of sleep disorders in Parkinson's disease showing distinct effects of dopamine D2-like receptor activation.

A mouse model of sleep disorders in Parkinson's disease showing distinct effects of dopamine D2-like receptor activation.

Journal: Progress in neurobiology

Published: August 07, 2023

Regulator of G-Protein Signalling 4 (RGS4) negatively modulates nociceptin/orphanin FQ opioid receptor signalling: Implication for l-Dopa-induced dyskinesia.

Regulator of G-Protein Signalling 4 (RGS4) negatively modulates nociceptin/orphanin FQ opioid receptor signalling: Implication for l-Dopa-induced dyskinesia.

Journal: British journal of pharmacology

Published: February 24, 2021

Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats.

Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats.

Journal: Neurobiology of disease

Published: June 04, 2020

Discovery and Structure-Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson's Disease Models.

Discovery and Structure-Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson's Disease Models.

Journal: Journal of medicinal chemistry

Published: January 18, 2020

6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata.

6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata.

Journal: British journal of pharmacology

Published: December 18, 2019

Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease.

Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease.

Journal: Neuropharmacology

Published: November 06, 2019

Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes.

Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes.

Journal: Pharmacology research & perspectives

Published: April 17, 2019

NOP Receptor Ligands and Parkinson's Disease.

NOP Receptor Ligands and Parkinson's Disease.

Journal: Handbook of experimental pharmacology

Published: January 29, 2019

Safinamide Differentially Modulates In Vivo Glutamate and GABA Release in the Rat Hippocampus and Basal Ganglia.

Safinamide Differentially Modulates In Vivo Glutamate and GABA Release in the Rat Hippocampus and Basal Ganglia.

Journal: The Journal of pharmacology and experimental therapeutics

Published: September 12, 2017

Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists.

Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists.

Journal: British journal of pharmacology

Published: April 13, 2017

Showing 1-11 of 11

Last Updated: 09/26/2026